Cardiopulmonary BypassNCT03146949
Blood Isoflurane Concentration and the Oxygenator
A study testing Sorin Inspire Oxygenator and Medtronic Affinity Fusion in people with Cardiopulmonary Bypass, run by University of Edinburgh at 1 site in United Kingdom.
Trial summary
This study compares two oxygenators commonly in use to establish whether they effect the amount of isoflurane in the patient's blood. Half of the patients will be placed in a group using the Sorin Inspire oxygenator and half into the group using the Medtronic Affinity Fusion oxygenator. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cardiopulmonary Bypass
- What is being tested?
- Sorin Inspire Oxygenator and Medtronic Affinity Fusion
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 25 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 5 Jan 2017to 26 Apr 2017
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- aged 18 years or older
- who have given their consent to participate
- scheduled for elective cardiac surgery requiring CPB
Who cannot join
- unwilling or unable to provide informed consent
- presenting for emergency surgery
- undergoing cardiac surgery without CPB
- in whom total intravenous anaesthesia (TIVA) is being used
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Does the Type of Oxygenator Influence Arterial Blood Concentration of Isoflurane During Cardiopulmonary Bypass?
This study compares two oxygenators commonly in use to establish whether they effect the amount of isoflurane in the patient's blood. Half of the patients will be placed in a group using the Sorin Inspire oxygenator and half into the group using the Medtronic Affinity Fusion oxygenator.
Read the detailed description
Cardiopulmonary bypass (CPB) is the keystone of most of these surgeries, as it allows for the maintenance of patient circulation without the requirement for a beating heart or breathing lungs. However, in doing so, CPB creates a unique set of difficulties associated with administering and maintaining anaesthesia. Firstly, the usual route of administration of inhalational anaesthetics, such as isoflurane, via the lungs is impossible. Secondly, clinical signs used to assess depth of anaesthesia, such as heart rate and systemic arterial blood pressure, are obscured by the mechanical support of the circulation. As a consequence, maintaining and assessing the depth of anaesthesia achieved during CBP provides challenges for the anaesthetists.
One common approach to administering anaesthesia during CBP involves the delivery of an inhalational anaesthetic agent, such as isoflurane, into the sweep gas supply to the oxygenator. Whilst classic terminology describes agents such as isoflurane as inhalational, in CPB this may cause confusion due to the delivery of the agent through the oxygenator as opposed to the lungs. Therefore, the alternative name of volatile anaesthetic agents is utilised in this protocol. Isoflurane concentrations ranging between 1% and 2.5% have been used by several anaesthetists at the Royal Infirmary of Edinburgh (RIE) for many years. This pragmatic approach has been found to produce clinically adequate depth of anaesthesia when either of the two oxygenators in routine use at the RIE are employed. Indeed, it has been shown using an electro-encephalographic (EEG) technique of assessing depth of anaesthesia, known as the Bispectral Index (BIS), that administering 2.5% isoflurane produces a more than adequate depth of anaesthesia. However, as discussed below, the interpretation of this finding is limited by the profound effect of hypothermia, which is commonly induced on CPB, has on BIS.
BIS is frequently utilised by anaesthetists to monitor anaesthetic depth. It involves real-time monitoring brain electrical waves using an EEG to produce a dimensionless number between 0 (no cortical brain activity) and 100 (awake), with 40 to 60 being widely accepted as a score suitable for general anaesthesia. Whilst BIS is frequently used in practice, as it has been shown to reduce anaesthetic awareness and increase emergence time, it is not without controversy as there is conflicting evidence regarding its reliability, particularly during CPB as low body temperature is known to affect its readings.
Considering the limitations of BIS, other methods can be employed to estimate depth of anaesthesia. The arterial blood concentration of the volatile agent is a good surrogate, as the concentration of agent in the brain will equilibrate with that of the blood.
Whilst this measurement provides a definitive value of how much anaesthetic agent is reaching the brain, it is impractical for clinical use because of the long duration and complexity of laboratory analysis that is required. Therefore, another approach can use the concentration of the volatile agent in the gases exhausted from the oxygenator in order to estimate the arterial blood concentration. This approach is analogous to using the end-tidal concentration that is expired from the lungs during routine general anaesthesia. Oxygenator exhaust, unlike arterial blood concentration, would be practical in a clinical scenario as the oxygenator exhaust from CPB can be attached to a standard anaesthetic gas monitor. Indeed, there is evidence that suggests measuring the oxygenator exhaust concentration of volatile anaesthetic agent is a good surrogate of arterial blood levels.
The oxygenator acts as the key interface between the patient's blood and volatile anaesthetic agent, and their availability is essential for CPB to go ahead. The RIE stock and routinely use two makes of oxygenator in case of manufacture supply problems - in which event the perfusionist would be familiar with using both. Both oxygenators are membrane in nature, consisting of microporous polypropylene hollow fibres. One is the Medtronic Affinity Fusion ('Fusion') and the other is Sorin Inspire ('Inspire'), with the choice of which is used being at the discretion of the perfusionist. Both oxygenators possess a similar design, with the patient's blood flowing over the fibers and a mixture of air and oxygen passing through them, allowing for gas exchange to occur, and crucially allowing the passage of volatile anaesthetic agent into the patient's blood. As the manufacture and design of various oxygenators are different, each possesses a unique set of transfer characteristics, which has been shown in bench tests to affect the uptake and elimination of isoflurane. The combined experience of the anaesthetists at the RIE indicates there is no clinical difference between the two different oxygenators in routine use or the resulting anaesthesia, however these bench tests suggest there may be some difference in transfer characteristics which may be established by small differences measured in the arterial blood level of isoflurane.
It also follows that if there are differences in arterial blood levels, other methods of measuring depth of anaesthesia, such as BIS and oxygen exhaust concentration of anaesthetic agent, may also show differences dependent on the oxygenator used. This is because they are measuring the same end-point, and should theoretically be related if they are accurately doing so.
Regardless of which of the two routine oxygenators is used during CPB, it has anecdotally been seen that no clinical difference in anaesthetic depth is observed. However, small differences may be detected by measuring the arterial blood concentration of isoflurane. If a difference exists, it suggests that anaesthetists should take the oxygenator transfer characteristics into account when deciding on which isoflurane concentration is to be used. If no difference is established, it will reassure anaesthetists that their interpretation of depth of anaesthesia in the clinical environment is correct.
- Conditions
- Cardiopulmonary Bypass
- Being tested
- Sorin Inspire Oxygenator, Medtronic Affinity Fusion
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Sorin Inspire OxygenatorDevice
This is an oxygenator manufactured by the Sorin group. It is a hollow fibre polypropylene oxygenator.
Medtronic Affinity FusionDevice
This is an oxygenator manufactured by the Medtronic group. It is a hollow fibre polypropylene oxygenator.
| Study group | Role | What they receive |
|---|---|---|
| Sorin Inspire Oxygenator | Active comparator | Sorin Inspire Oxygenator is used on the cardiopulmonary bypass machine Receives: Device: Sorin Inspire Oxygenator |
| Medtronic Affinity Fusion Oxygenator | Active comparator | Medtronic Affinity Fusion Oxygenator is used on the cardiopulmonary bypass machine Receives: Device: Medtronic Affinity Fusion |
What is being measured
The primary outcome is the main question the study is designed to answer.
Arterial blood concentration of isoflurane
6ml sample of blood will be taken at three time points during an operation requiring cardiopulmonary bypass. This blood will be analysed using gas chromatography and mass spectrometry in order to quantify isoflurane concentrations.
Mean values will be calculated for each participant, and then an overall mean will be produced for each oxygenator. This will then be compared using independent-samples t-test.
Measured: Application of aortic cross clamp, 20 minutes after application, removal of aortic cross clamp.
Secondary outcomes (3)
Change in Bispectral Index Score (BIS)
A five-electrode BIS monitor will be placed on the forehead at the beginning of surgery. This will display a BIS Score on the Mindray monitor.
Measured: Application of aortic cross clamp, 20 minutes after application, removal of aortic cross clamp.
Change in arterial temperature
Arterial temperature is measured by the cardiopulmonary bypass machine and displayed continuously on the perfusionist's monitors. It will be read directly from these monitors.
Measured: Application of aortic cross clamp, 20 minutes after application, removal of aortic cross clamp.
Change in exhaust isoflurane concentration
The cardiopulmonary bypass exhaust output will be analysed by infrared gas analysis, which will be displayed as a reading on the Mindray monitor throughout the operation.
Measured: Application of aortic cross clamp, 20 minutes after application, removal of aortic cross clamp.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 May 2017
- Study start5 Jan 2017
- Primary completion26 Apr 2017
- Study completion26 Apr 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cardiopulmonary BypassStudies of the same condition, open and under way.
- More trials run by University of EdinburghThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 25 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Edinburgh
- Sponsor type
- University, hospital or other
- Collaborators
- NHS Lothian
- Responsible party
- Sponsor
- Investigators
- Peter Alston, Principal investigator, Honorary Clinical Senior Lecturer and Consultant Anaesthetist
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03146949
- Sponsor's protocol ID
- AC16130
- Status last verified
- May 2024
- First submitted
- 6 Apr 2017
- Last updated
- 23 May 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 May 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Does the Type of Oxygenator Influence Arterial Blood Concentration of Isoflurane During Cardiopulmonary Bypass?
- ClinicalTrials.gov ID
- NCT03146949
- Acronym / sponsor ID
- AC16130
- Conditions
- Cardiopulmonary Bypass
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 25 participants (actual)
- Lead sponsor
- University of EdinburghUniversity, hospital or other
- Collaborators
- NHS Lothian
- Study start
- 5 Jan 2017 (actual)
- Primary completion
- 26 Apr 2017 (actual)
- Study completion
- 26 Apr 2017 (actual)
- First posted
- 10 May 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study compares two oxygenators commonly in use to establish whether they effect the amount of isoflurane in the patient's blood. Half of the patients will be placed in a group using the Sorin Inspire oxygenator and half into the group using the Medtronic Affinity Fusion oxygenator.
Detailed description
Cardiopulmonary bypass (CPB) is the keystone of most of these surgeries, as it allows for the maintenance of patient circulation without the requirement for a beating heart or breathing lungs. However, in doing so, CPB creates a unique set of difficulties associated with administering and maintaining anaesthesia. Firstly, the usual route of administration of inhalational anaesthetics, such as isoflurane, via the lungs is impossible. Secondly, clinical signs used to assess depth of anaesthesia, such as heart rate and systemic arterial blood pressure, are obscured by the mechanical support of the circulation. As a consequence, maintaining and assessing the depth of anaesthesia achieved during CBP provides challenges for the anaesthetists.
One common approach to administering anaesthesia during CBP involves the delivery of an inhalational anaesthetic agent, such as isoflurane, into the sweep gas supply to the oxygenator. Whilst classic terminology describes agents such as isoflurane as inhalational, in CPB this may cause confusion due to the delivery of the agent through the oxygenator as opposed to the lungs. Therefore, the alternative name of volatile anaesthetic agents is utilised in this protocol. Isoflurane concentrations ranging between 1% and 2.5% have been used by several anaesthetists at the Royal Infirmary of Edinburgh (RIE) for many years. This pragmatic approach has been found to produce clinically adequate depth of anaesthesia when either of the two oxygenators in routine use at the RIE are employed. Indeed, it has been shown using an electro-encephalographic (EEG) technique of assessing depth of anaesthesia, known as the Bispectral Index (BIS), that administering 2.5% isoflurane produces a more than adequate depth of anaesthesia. However, as discussed below, the interpretation of this finding is limited by the profound effect of hypothermia, which is commonly induced on CPB, has on BIS.
BIS is frequently utilised by anaesthetists to monitor anaesthetic depth. It involves real-time monitoring brain electrical waves using an EEG to produce a dimensionless number between 0 (no cortical brain activity) and 100 (awake), with 40 to 60 being widely accepted as a score suitable for general anaesthesia. Whilst BIS is frequently used in practice, as it has been shown to reduce anaesthetic awareness and increase emergence time, it is not without controversy as there is conflicting evidence regarding its reliability, particularly during CPB as low body temperature is known to affect its readings.
Considering the limitations of BIS, other methods can be employed to estimate depth of anaesthesia. The arterial blood concentration of the volatile agent is a good surrogate, as the concentration of agent in the brain will equilibrate with that of the blood.
Whilst this measurement provides a definitive value of how much anaesthetic agent is reaching the brain, it is impractical for clinical use because of the long duration and complexity of laboratory analysis that is required. Therefore, another approach can use the concentration of the volatile agent in the gases exhausted from the oxygenator in order to estimate the arterial blood concentration. This approach is analogous to using the end-tidal concentration that is expired from the lungs during routine general anaesthesia. Oxygenator exhaust, unlike arterial blood concentration, would be practical in a clinical scenario as the oxygenator exhaust from CPB can be attached to a standard anaesthetic gas monitor. Indeed, there is evidence that suggests measuring the oxygenator exhaust concentration of volatile anaesthetic agent is a good surrogate of arterial blood levels.
The oxygenator acts as the key interface between the patient's blood and volatile anaesthetic agent, and their availability is essential for CPB to go ahead. The RIE stock and routinely use two makes of oxygenator in case of manufacture supply problems - in which event the perfusionist would be familiar with using both. Both oxygenators are membrane in nature, consisting of microporous polypropylene hollow fibres. One is the Medtronic Affinity Fusion ('Fusion') and the other is Sorin Inspire ('Inspire'), with the choice of which is used being at the discretion of the perfusionist. Both oxygenators possess a similar design, with the patient's blood flowing over the fibers and a mixture of air and oxygen passing through them, allowing for gas exchange to occur, and crucially allowing the passage of volatile anaesthetic agent into the patient's blood. As the manufacture and design of various oxygenators are different, each possesses a unique set of transfer characteristics, which has been shown in bench tests to affect the uptake and elimination of isoflurane. The combined experience of the anaesthetists at the RIE indicates there is no clinical difference between the two different oxygenators in routine use or the resulting anaesthesia, however these bench tests suggest there may be some difference in transfer characteristics which may be established by small differences measured in the arterial blood level of isoflurane.
It also follows that if there are differences in arterial blood levels, other methods of measuring depth of anaesthesia, such as BIS and oxygen exhaust concentration of anaesthetic agent, may also show differences dependent on the oxygenator used. This is because they are measuring the same end-point, and should theoretically be related if they are accurately doing so.
Regardless of which of the two routine oxygenators is used during CPB, it has anecdotally been seen that no clinical difference in anaesthetic depth is observed. However, small differences may be detected by measuring the arterial blood concentration of isoflurane. If a difference exists, it suggests that anaesthetists should take the oxygenator transfer characteristics into account when deciding on which isoflurane concentration is to be used. If no difference is established, it will reassure anaesthetists that their interpretation of depth of anaesthesia in the clinical environment is correct.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Sorin Inspire Oxygenator | Active comparator | Device: Sorin Inspire OxygenatorSorin Inspire Oxygenator is used on the cardiopulmonary bypass machine |
| Medtronic Affinity Fusion Oxygenator | Active comparator | Device: Medtronic Affinity FusionMedtronic Affinity Fusion Oxygenator is used on the cardiopulmonary bypass machine |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- aged 18 years or older
- who have given their consent to participate
- scheduled for elective cardiac surgery requiring CPB
Key exclusion criteria (4 listed)
- unwilling or unable to provide informed consent
- presenting for emergency surgery
- undergoing cardiac surgery without CPB
- in whom total intravenous anaesthesia (TIVA) is being used
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Sorin Inspire OxygenatorThis is an oxygenator manufactured by the Sorin group. It is a hollow fibre polypropylene oxygenator. | Device | Sorin Inspire Oxygenator |
| Medtronic Affinity FusionThis is an oxygenator manufactured by the Medtronic group. It is a hollow fibre polypropylene oxygenator. | Device | Medtronic Affinity Fusion Oxygenator |
Primary outcome
Arterial blood concentration of isoflurane
Time frame: Application of aortic cross clamp, 20 minutes after application, removal of aortic cross clamp.
6ml sample of blood will be taken at three time points during an operation requiring cardiopulmonary bypass. This blood will be analysed using gas chromatography and mass spectrometry in order to quantify isoflurane concentrations. Mean values will be calculated for each participant, and then an overall mean will be produced for each oxygenator. This will then be compared using independent-samples t-test.
3 secondary outcomes
Change in Bispectral Index Score (BIS)
Time frame: Application of aortic cross clamp, 20 minutes after application, removal of aortic cross clamp.
Change in arterial temperature
Time frame: Application of aortic cross clamp, 20 minutes after application, removal of aortic cross clamp.
Change in exhaust isoflurane concentration
Time frame: Application of aortic cross clamp, 20 minutes after application, removal of aortic cross clamp.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 May 2024.
- Individual participant dataSharing planned: No
Related trials for Cardiopulmonary Bypass
Not yet recruitingPhase 3
SGB for Prevention of Postop A-Fib After Cardiac SurgeryTrial
Atrial Fibrillation, Postoperative Atrial Fibrillation
Recruiting
A Study to Understand How Cardiac Surgery-associated Acute Kidney Injury Develops in Participants Who Undergo Heart Surgery With the Use of Heart-lung Machine
Cardiac Surgery-associated Acute Kidney Injury
Active, not recruiting
Low Tidal Volume Ventilation With Hyperoxia Avoidance During Cardiopulmonary Bypass (The FOCUS Trial)
Cardiac Surgery
Not yet recruiting
Continuous Glucose Monitoring in Patients Undergoing Cardiopulmonary Bypass
Glucose Metabolism Disorders (Including Diabetes Mellitus)
Recruiting
Mechanisms and Intervention Strategies of Perioperative Glycemic Variability on Postoperative Delirium
Cardiac Surgery With Cardiopulmonary Bypass, Postoperative Delirium
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Peter Alston principal investigator
Honorary Clinical Senior Lecturer and Consultant Anaesthetist
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Sorin Inspire Oxygenator and Medtronic Affinity Fusion in people with Cardiopulmonary Bypass, run by University of Edinburgh at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 May 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Arterial blood concentration of isoflurane (time frame: Application of aortic cross clamp, 20 minutes after application, removal of aortic cross clamp.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 May 2024.